Compass cuts 30% of staff as late-stage psilocybin drug trials face new delays

Green Market Report
By Adam JacksonOct 31, 2024, 9:27 am34 pts
Compass Pathways (NASDAQ: CMPS) plans to cut about 30% of its workforce and halt early-stage research programs as the firm focuses resources on completing late-stage trials of its lead COMP360 program. The London-based company announced the restructuring alongside third-quarter financial results that showed a…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

The Hash Co completes asset transfer, name change 59

VENTY Vaporizer Review: A Cutting-Edge Portable Powerhouse 33

About NewsBudz

NewsBudz is a marijuana and medical cannabis news app. The site delivers a daily feed of the latest cannabis news. We aggregate over 30 of the web's best sources for news about marijuana, hemp and legalization to keep you informed.

Stay on top of the latest news headlines, trends and developments worldwide around recreational and medical marijuana. Sit back and relax, while you read learn and share. On the web or your mobile device, NewsBudz is your cannabis news stream.